Vaccine Scheduler

Greece: Recommended vaccinations

	General recommendation
	Recommendation for specific groups only
	Catch-up (e.g. if previous doses missed)
	Vaccination not funded by the National Health system
	Mandatory vaccination

	Birth	Months												Years
	Birth	2	3	4	5	6	10	11	12	15	18	19	23	2	3	4	5	6	7	9	10	11	12	13	15	18	19	36	45	50	59	60	64	65	74	≥ 75
Coronavirus disease (COVID-19)¹						COVID-19⁷																										COVID-19⁷

RSV																																RSV⁸				RSV⁹

tuberculosis	BCG¹⁰	BCG

rotavirus infection²		ROTA		ROTA		ROTA

diphtheria		D		D		D			D	D		D				D			d			d		d		d¹¹
tetanus		TT		TT		TT			TT	TT		TT				TT			TT			TT		TT		TT¹¹
pertussis		acP		acP		acP			acP	acp		acp				acP			acp			acp		acp		acp¹²
poliomyelitis		IPV		IPV		IPV						IPV				IPV			IPV							IPV¹¹
Haemophilus influenzae type b infection		Hib		Hib		Hib		Hib		Hib		Hib						Hib
hepatitis B	HepB¹³	HepB		HepB		HepB						HepB														HepB¹⁴

pneumococcal disease³		PCV15 or PCV20		PCV15 or PCV20					PCV15 or PCV20¹⁵								PCV20																	PCV20

meningococcal disease⁴		MenB		MenB			MenC¹⁶		MenB													MCV4		MCV4		MCV4/MenB

measles⁵									MEAS		MEAS			MEAS		MEAS											MEAS¹⁷
mumps									MUMPS		MUMPS			MUMPS		MUMPS											MUMPS¹⁷
rubella									RUBE		RUBE			RUBE		RUBE											RUBE¹⁷

varicella									VAR		VAR			VAR		VAR¹⁸

human papillomavirus infection																				HPV9 (F/M)¹⁹					HPV9 (F/M)²⁰		HPV9 (F/M)²¹

influenza						IIV3²²												IIV3														IIV3/aIIV3/IIV3-HD²³

herpes zoster⁶																										ZOS²⁴						ZOS²⁵

hepatitis A														HepA					HepA								HepA

Version:

Footnotes:

https://emvolio.gov.gr/
2 doses of RV1 (month 2 and 4) OR 3 doses of RV5 (month 2, 4 and 6)
PPSV23 recommended from 2 years of age in at-risk groups
MenACWY is recommended to all adolescents aged 11-12 years. It is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 6 months of age are recommended 3 doses at ages 2, 4 and 12 months (MenACWY-TT vaccine); Infants starting vaccination between 7 and 24 months: 2 doses, 2nd dose to is administered at least 12 weeks after the first dose (MenACWY-TT vaccine); Children starting vaccination after 2 years of age: 2 doses with 8 weeks interval (MenACWY-CRM or MenACWY-TT vaccine); In children who remain at high risk, a booster dose is recommended 3-5 years after completion of their primary course. The MenB-4C is recommended to healthy infants in two doses at 2 and 4 months of age, with a booster dose at 12-15 months of age. The MenB-4C is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 5 months of age are recommended 4 doses at ages 2, 4, 6 and 12–15 months (MenB-4C); Infants and toddlers starting vaccination at 6 to 23 months of age: 2 doses with minimum 8 weeks interval and a booster dose at age 12–23 months (MenB-4C); Children starting vaccination at 2 to 10 years of age: 2 doses with minimum 8 weeks interval (MenB-4C); Children starting vaccination from the age of 11 years: 2 doses with minimum interval of 1 month (MenB-4C); Individuals aged 10 years and above can be vaccinated with MenB-fHbp with a 3-dose regimen at 0, 1–2, 6 months. More details available at: https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/ethniko-programma-emboliasmwn-epe-paidiwn-kai-efhbwn/13728-tropopoihsh-ethnikoy-programmatos-emboliasmwn-paidiwn-kai-efhbwn-2025-xronodiagramma-kai-systaseis
21 Sept. 2017: temporary recommendation for measles vaccination in Greece. First Dose at 12 months of age, Second dose 3 months later or 4 weeks after Dose 1 in specific groups
for detailled information refer to https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/alles-systaseis-ths-ethnikhs-epitrophs-emboliasmwn/11437-skeptiko-emboliasmoy-gia-ton-erphta-zwsthra-aprilios-2023
6m-59y high risk groups, 60-74 1 dose, = 75y 2 doses , immunocompromised 2 doses (interval 6 months)
60-74 high risk groups
All adults older than 75 years of age.
Vaccination is also recommended for infants and children up to the age of 5 years who belong to an increased risk groups and who have not been previously vaccinated
Booster dose 18- 25 y with Tdap or Tdap-IPV, followed by Td or Tdap every 10 y.
Booster dose 18- 25 y with Tdap or Tdap-IPV, followed by Td or Tdap every 10 y. A single dose of Tdap or Tdap-IPV vaccine should be administered in each pregnancy, preferably from 27 to 36 weeks of gestation, as well as to unvaccinated women who have recently given birth, regardless of the interval between previous Tdacp vaccination.
Babies born to a mother infected with hepatitis B (or with unknown status) will be offered a first vaccine dose at birth simultaneously with HB immunoglobulin.
Three doses, high risk groups
Only for premature babies, the recommended schedule consists of 3 primary doses + 1 booster dose (3+1), otherwise the recommended schedule is 2+1.
MenC: 1 dose at the age of 10 months
For individuals born after 1970 (one or two doses depending on vaccination history and clinical history)
For unvaccinated individuals born after 1990. Two doses recommended to people belonging to specific occupational categories.
Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2023). 2 doses scheme up to 15 years with 6 months interval between doses, thereafter 3 doses. for specific at-risk groups vaccination can be extended up to 26 years.
Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2025). 2 doses scheme up to 18 years. for specific at-risk groups vaccination can be extended up to 26 years.
Unvaccinated women and men, aged 19-45 years, belonging to high risk groups.
Since 2024 flu vaccination is recommended to all children between 6 months -5 years of age. In addition, Greece has recommendations for children and adolescents (5-18 years) belonging to high-risk groups. Source: https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/metadotika-kai-mh-metadotika-noshmata/c388-egkyklioi/13711-odhgies-gia-thn-epoxikh-griph-2025-2026-ndash-antigripikos-emboliasmos
TIV-HD and aTIV recommended in adults aged >= 65 years.
Two doses (RZV vaccine) in immunocompromised.
RZV 2 doses

More information available at:
https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/

Last update : 10 February 2025